FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	ırden									

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Gregory Ginger</u>						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]										eck all appli Directo	cable) or	ng Person(s) to Iss		vner
(Last) (First) (Middle) BIOGEN INC. 225 BINNEY ST.						3. Date of Earliest Transaction (Month/Day/Year) 08/01/2017										helow)	(give title VP, Huma	an Re	Other (s below) esources	вреспу Поверения предоставляющий предоставляющий предоставляющий предоставляющий предоставляющий предоставляющий пред
(Street) CAMBRIDGE MA 02142 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - Non	-Deriv	ative	Sec	uritie	s Ac	qui	ired, I	Disp	osed o	of, or B	ene	eficial	ly Owned	k			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					ar) E	2A. Deemed Execution Date, if any (Month/Day/Year)		, Transaction Dispos Code (Instr. 5)		Dispose	ities Acqı d Of (D) (l			Benefici	ies For ially (D) Following (I) (n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount	(A) (D)	or	Price	Transac (Instr. 3	ction(s)			(111311.4)
Common Stock 08/01					1/2017					Α	860		0 A		\$ <mark>0</mark>	8	860		D	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	3A. Deemec Execution E if any (Month/Day	ution Date,		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title a Amount Securiti Underly Derivati (Instr. 3	of es ng /e Se		8. Price of Derivative Security (Instr. 5)		s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
					Code	V	(A)	(D)	Date Exe	e ercisable		xpiration ate	Title	OI No	umber					
Restricted Stock Unit	\$0	08/01/2017			Α		1,280			(1)	08	3/01/2020	Commo	1 1	,280	\$0	1,280		D	

Explanation of Responses:

1. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date)].

<u>Suzanne Murray, Attorney in</u> <u>Fact for Ginger Gregory</u>

08/03/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.